• 1
    National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C: 2002 June 10–12, 2002. Hepatology 2002; 36 (5 Suppl. 1): S320.
  • 2
    Cacoub P. [Treatment of hepatitic C virus infection after the French 2002 Consensus Conference]. Rev Med Interne 2002; 23: 88992.
  • 3
    Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 114771.
  • 4
    Jen JF, Glue P, Gupta S, Zambas D, Hajian G. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit 2000; 22: 55565.
  • 5
    Larrat S, Stanke-Labesque F, Plages A, Zarski JP, Bessard G, Souvignet C. Ribavirin quantification in combination treatment of chronic hepatitis C. Antimicrob Agents Chemother 2003; 47: 1249.
  • 6
    Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005; 41: 2759.
  • 7
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 97582.
  • 8
    Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM, PEGASYS International Study Group. Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 34655.
  • 9
    Rodriguez-Torres M, Torriani FJ, Soriano V, Borucki MJ, Lissen E, Sulkowski M, Dieterich D, Wang K, Gries J-M, Hoggard PG, Back DJ for the APRICOT Study Group. Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with HIV-HCV co-infection: results of a randomized clinical study. Antimicrob Agents Chemother 2005; 49: 39974008.
  • 10
    Beal SL, Sheiner LB. NONMEM Users Guides. San Francisco: NONMEM Project Group, University of California at San Francisco 1998.
  • 11
    MathSoft Inc. S-Plus 2000. Modern Statistics and Advanced Graphics. Seattle, WA: Mathsoft 2000.
  • 12
    Jonsson EN, Karlsson MO. Xpose – an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comp Meth Prog Biomed 1999; 58: 5164.
  • 13
    Preston SL, Drusano GL, Glue P, Nash J, Gupta SK, McNamara P. Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. Antimicrob Agents Chemother 1999; 43: 24516.
  • 14
    Homma M, Matsuzaki Y, Inoue Y, Shibata M, Mitamura K, Tanaka N, Kohda Y. Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia. Clin Gastroenterol Hepatol 2004; 2: 3379.
  • 15
    Wade JR, Kelman AW, Howie CA, Whiting B. Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis. J Pharmacokinet Biopharm 1993; 21: 20922.
  • 16
    Bruchfeld A, Lindahl K, Schvarcz R, Stahle L. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther Drug Monit 2002; 24: 7018.
  • 17
    Snoeck E, Wade J, Duff F, Lamb M, Jorga K. Predicting SVR and anemia in HCV-patients treated with PEG-IFN alfa-2a (40KD:) plus ribavirin. Br J Clin Pharmacol; submitted for publication.